ESMO 2017 Congress Report
ESMO 2017 single articles:
• Preface
• Immunotherapy: once more at the cutting edge of progress
• Immunostimulation as a promising approach in SCLC
• Randomised findings on CT-based follow-up after resection of early NSCLC
• EGFR-mutant lung cancer: sequencing as a major topic in light of new data
• Interview: Survival is the result of multiple treatment lines
• Reaching unprecedented outcome dimensions in malignant mesothelioma
• Characteristics and outcomes for SCLC arising from transformation
• ALK-positive NSCLC: updates on crizotinib and alectinib
• Rare driver mutations: BRAF- and HER2-mutant NSCLC
Full Report (English)